Forced Technology Transfer Hinders Innovation In China – USTR
This article was originally published in PharmAsia News
China still has major intellectual property enforcement problems that unfairly disadvantage U.S. IP rights holders in the country.
You may also be interested in...
China To De-link Indigenous Innovation And Public Procurement Policies - U.S.-China Strategic And Economic Dialogue
WASHINGTON - In a positive move for the life sciences industry and others conducting business in China, Chinese leaders have agreed to de-link indigenous innovation policies from government procurement, a decision that - if fully implemented - would provide a fairer competitive environment for foreign-invested enterprises in China
The failure of U.S. trading partners to adequately protect pharmaceutical test data remains one of the top concerns of the United States Trade Representative in its 2011 Special 301 Report on intellectual property rights
Intellectual Property Protection: Foreign Governments Get To Argue Their Case To USTR Before Publication Of "Watch Lists"
For the first time, the U.S. Trade Representative is giving foreign governments and others a chance to publicly testify before issuing its 2010 Special 301 report on countries it deems do not provide adequate protection of intellectual property rights